{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:11:37Z","timestamp":1788498697249,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T00:00:00Z","timestamp":1650931200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["T32DK07245"],"award-info":[{"award-number":["T32DK07245"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose:<\/jats:title>\n                <jats:p>Literature regarding endogenous Cushing syndrome (CS) largely focuses on the challenges of diagnosis, subtyping, and treatment. The enigmatic phenomenon of glucocorticoid withdrawal syndrome (GWS), due to rapid reduction in cortisol exposure following treatment of CS, is less commonly discussed but also difficult to manage. We highlight the clinical approach to navigating patients from GWS and adrenal insufficiency to full hypothalamic-pituitary-adrenal (HPA) axis recovery.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods:<\/jats:title>\n                <jats:p>We review the literature on the pathogenesis of GWS and its clinical presentation. We provide strategies for glucocorticoid dosing and tapering, HPA axis testing, as well as pharmacotherapy and ancillary treatments for GWS symptom management.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results:<\/jats:title>\n                <jats:p>GWS can be difficult to differentiate from adrenal insufficiency and CS recurrence, which complicates glucocorticoid dosing and tapering regimens. Monitoring for HPA axis recovery requires both clinical and biochemical assessments. The most important intervention is reassurance to patients that GWS symptoms portend a favorable prognosis of sustained remission from CS, and GWS typically resolves as the HPA axis recovers. GWS also occurs during medical management of CS, and gradual dose titration based primarily on symptoms is essential to maintain adherence and to eventually achieve disease control. Myopathy and neurocognitive dysfunction can be chronic complications of CS that do not completely recover.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions:<\/jats:title>\n                <jats:p>Due to limited data, no guidelines have been developed for management of GWS. Nevertheless, this article provides overarching themes derived from published literature plus expert opinion and experience. Future studies are needed to better understand the pathophysiology of GWS to guide more targeted and optimal treatments.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-022-01218-y","type":"journal-article","created":{"date-parts":[[2022,4,26]],"date-time":"2022-04-26T06:02:53Z","timestamp":1650952973000},"page":"393-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3696-8836","authenticated-orcid":false,"given":"Xin","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3101-5320","authenticated-orcid":false,"given":"James W.","family":"Findling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6815-6181","authenticated-orcid":false,"given":"Richard J.","family":"Auchus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,26]]},"reference":[{"key":"1218_CR1","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11154-010-9143-3","volume":"11","author":"TB Carroll","year":"2010","unstructured":"Carroll TB, Findling JW (2010) The diagnosis of Cushing\u2019s syndrome. Rev Endocr Metab Disord 11:147\u2013153. https:\/\/doi.org\/10.1007\/s11154-010-9143-3","journal-title":"Rev Endocr Metab Disord"},{"key":"1218_CR2","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9:847\u2013875. https:\/\/doi.org\/10.1016\/S2213-8587(21)00235-7","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1218_CR3","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK, Biller BMK, Findling JW et al (2015) Treatment of Cushing\u2019s Syndrome: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100:2807\u20132831. https:\/\/doi.org\/10.1210\/jc.2015-1818","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR4","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BMK Biller","year":"2008","unstructured":"Biller BMK, Grossman AB, Stewart PM et al (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454\u20132462. https:\/\/doi.org\/10.1210\/jc.2007-2734","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR5","doi-asserted-by":"publisher","first-page":"962","DOI":"10.4158\/EP171787.OR","volume":"23","author":"EB Geer","year":"2017","unstructured":"Geer EB, Shafiq I, Gordon MB et al (2017) BIOCHEMICAL CONTROL DURING LONG-TERM FOLLOW-UP OF 230 ADULT PATIENTS WITH CUSHING DISEASE: A MULTICENTER RETROSPECTIVE STUDY. Endocr Pract 23:962\u2013970. https:\/\/doi.org\/10.4158\/EP171787.OR","journal-title":"Endocr Pract"},{"key":"1218_CR6","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1056\/NEJMoa1105743","volume":"366","author":"A Colao","year":"2012","unstructured":"Colao A, Petersenn S, Newell-Price J et al (2012) A 12-Month Phase 3 Study of Pasireotide in Cushing\u2019s Disease. N Engl J Med 366:914\u2013924. https:\/\/doi.org\/10.1056\/NEJMoa1105743","journal-title":"N Engl J Med"},{"key":"1218_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","volume":"6","author":"A Lacroix","year":"2018","unstructured":"Lacroix A, Gu F, Gallardo W et al (2018) Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial. Lancet Diabetes Endocrinol 6:17\u201326. https:\/\/doi.org\/10.1016\/S2213-8587(17)30326-1","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1218_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1210\/jc.2008-1533","volume":"94","author":"R Pivonello","year":"2009","unstructured":"Pivonello R, De Martino MC, Cappabianca P et al (2009) The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery. J Clin Endocrinol Metab 94:223\u2013230. https:\/\/doi.org\/10.1210\/jc.2008-1533","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","volume":"8","author":"R Pivonello","year":"2020","unstructured":"Pivonello R, Fleseriu M, Newell-Price J et al (2020) Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol 8:748\u2013761. https:\/\/doi.org\/10.1016\/S2213-8587(20)30240-0","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1218_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","volume":"62","author":"F Ceccato","year":"2018","unstructured":"Ceccato F, Zilio M, Barbot M et al (2018) Metyrapone treatment in Cushing\u2019s syndrome: a real-life study. Endocrine 62:701\u2013711. https:\/\/doi.org\/10.1007\/s12020-018-1675-4","journal-title":"Endocrine"},{"key":"1218_CR11","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","volume":"7","author":"M Fleseriu","year":"2019","unstructured":"Fleseriu M, Pivonello R, Elenkova A et al (2019) Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes Endocrinol 7:855\u2013865. https:\/\/doi.org\/10.1016\/S2213-8587(19)30313-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1218_CR12","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Guignat L, Giraud P et al (2014) Ketoconazole in Cushing\u2019s disease: is it worth a try? J Clin Endocrinol Metab 99:1623\u20131630. https:\/\/doi.org\/10.1210\/jc.2013-3628","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR13","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BMK, Findling JW et al (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97:2039\u20132049. https:\/\/doi.org\/10.1210\/jc.2011-3350","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR14","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-20-1088","volume":"184","author":"M Reincke","year":"2021","unstructured":"Reincke M, Albani A, Assie G et al (2021) Corticotroph tumor progression after bilateral adrenalectomy (Nelson\u2019s syndrome): systematic review and expert consensus recommendations. Eur J Endocrinol 184:P1\u2013P16. https:\/\/doi.org\/10.1530\/EJE-20-1088","journal-title":"Eur J Endocrinol"},{"key":"1218_CR15","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1210\/jc.2011-0456","volume":"96","author":"JR Lindsay","year":"2011","unstructured":"Lindsay JR, Oldfield EH, Stratakis CA, Nieman LK (2011) The Postoperative Basal Cortisol and CRH Tests for Prediction of Long-Term Remission from Cushing\u2019s Disease after Transsphenoidal Surgery. J Clin Endocrinol Metab 96:2057\u20132064. https:\/\/doi.org\/10.1210\/jc.2011-0456","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR16","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1007\/s11102-012-0455-z","volume":"16","author":"N Hameed","year":"2013","unstructured":"Hameed N, Yedinak CG, Brzana J et al (2013) Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing\u2019s disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience. Pituitary 16:452\u2013458. https:\/\/doi.org\/10.1007\/s11102-012-0455-z","journal-title":"Pituitary"},{"key":"1218_CR17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12902-015-0055-9","volume":"15","author":"J Ramm-Pettersen","year":"2015","unstructured":"Ramm-Pettersen J, Halvorsen H, Evang JA et al (2015) Low immediate postoperative serum-cortisol nadir predicts the short-term, but not long-term, remission after pituitary surgery for Cushing\u2019s disease. BMC Endocr Disord 15:62. https:\/\/doi.org\/10.1186\/s12902-015-0055-9","journal-title":"BMC Endocr Disord"},{"key":"1218_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1530\/EJE-17-0873","volume":"178","author":"N Ironside","year":"2018","unstructured":"Ironside N, Chatain G, Asuzu D et al (2018) Earlier post-operative hypocortisolemia may predict durable remission from Cushing\u2019s disease. Eur J Endocrinol 178:255\u2013263. https:\/\/doi.org\/10.1530\/EJE-17-0873","journal-title":"Eur J Endocrinol"},{"key":"1218_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1210\/er.2001-0014","volume":"24","author":"Z Hochberg","year":"2003","unstructured":"Hochberg Z, Pacak K, Chrousos GP (2003) Endocrine Withdrawal Syndromes. Endocr Rev 24:523\u2013538. https:\/\/doi.org\/10.1210\/er.2001-0014","journal-title":"Endocr Rev"},{"key":"1218_CR20","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/0002-9343(80)90358-7","volume":"68","author":"RB Dixon","year":"1980","unstructured":"Dixon RB, Christy NP (1980) On the various forms of corticosteroid withdrawal syndrome. Am J Med 68:224\u2013230. https:\/\/doi.org\/10.1016\/0002-9343(80)90358-7","journal-title":"Am J Med"},{"key":"1218_CR21","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1210\/jcem-25-9-1207","volume":"25","author":"ND AMATRUDA TT JR","year":"1965","unstructured":"AMATRUDA TT ND JR (1965) Certain Endocrine and Metabolic Facets of the Steroid Withdrawal Syndrome. J Clin Endocrinol Metab 25:1207\u20131217. https:\/\/doi.org\/10.1210\/jcem-25-9-1207","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR22","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1210\/jcem.82.3.3834","volume":"82","author":"LD Dorn","year":"1997","unstructured":"Dorn LD, Burgess ES, Friedman TC et al (1997) The Longitudinal Course of Psychopathology in Cushing\u2019s Syndrome after Correction of Hypercortisolism. J Clin Endocrinol Metab 82:912\u2013919. https:\/\/doi.org\/10.1210\/jcem.82.3.3834","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR23","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1001\/jama.1992.03480090092034","volume":"267","author":"GP Chrousos","year":"1992","unstructured":"Chrousos GP, Gold PW (1992) The Concepts of Stress and Stress System Disorders: Overview of Physical and Behavioral Homeostasis. JAMA 267:1244\u20131252. https:\/\/doi.org\/10.1001\/jama.1992.03480090092034","journal-title":"JAMA"},{"key":"1218_CR24","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1210\/jcem-72-2-260","volume":"72","author":"MA Kling","year":"1991","unstructured":"Kling MA, Roy A, Doran AR et al (1991) Cerebrospinal fluid immunoreactive corticotropin-releasing hormone and adrenocorticotropin secretion in Cushing\u2019s disease and major depression: potential clinical implications. J Clin Endocrinol Metab 72:260\u2013271. https:\/\/doi.org\/10.1210\/jcem-72-2-260","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1210\/jcem.77.1.8392083","volume":"77","author":"MT Gomez","year":"1993","unstructured":"Gomez MT, Magiakou MA, Mastorakos G, Chrousos GP (1993) The pituitary corticotroph is not the rate limiting step in the postoperative recovery of the hypothalamic-pituitary-adrenal axis in patients with Cushing syndrome. J Clin Endocrinol Metab 77:173\u2013177. https:\/\/doi.org\/10.1210\/jcem.77.1.8392083","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR26","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1365-2826.1995.tb00665.x","volume":"7","author":"EA Young","year":"1995","unstructured":"Young EA, Kwak SP, Kottak J (1995) Negative feedback regulation following administration of chronic exogenous corticosterone. J Neuroendocrinol 7:37\u201345. https:\/\/doi.org\/10.1111\/j.1365-2826.1995.tb00665.x","journal-title":"J Neuroendocrinol"},{"key":"1218_CR27","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1210\/jcem.81.6.8964868","volume":"81","author":"DA Papanicolaou","year":"1996","unstructured":"Papanicolaou DA, Tsigos C, Oldfield EH, Chrousos GP (1996) Acute glucocorticoid deficiency is associated with plasma elevations of interleukin-6: does the latter participate in the symptomatology of the steroid withdrawal syndrome and adrenal insufficiency? J Clin Endocrinol Metab 81:2303\u20132306. https:\/\/doi.org\/10.1210\/jcem.81.6.8964868","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1227\/NEU.0b013e31822dda2c","volume":"70","author":"I Ciric","year":"2012","unstructured":"Ciric I, Zhao J-C, Du H et al (2012) Transsphenoidal surgery for Cushing disease: experience with 136 patients. Neurosurgery 70:70\u201380 discussion 80\u201381. https:\/\/doi.org\/10.1227\/NEU.0b013e31822dda2c","journal-title":"Neurosurgery"},{"key":"1218_CR29","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1530\/EJE-12-0921","volume":"168","author":"KI Alexandraki","year":"2013","unstructured":"Alexandraki KI, Kaltsas GA, Isidori AM et al (2013) Long-term remission and recurrence rates in Cushing\u2019s disease: predictive factors in a single-centre study. Eur J Endocrinol 168:639\u2013648. https:\/\/doi.org\/10.1530\/EJE-12-0921","journal-title":"Eur J Endocrinol"},{"key":"1218_CR30","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/17446651.2020.1802243","volume":"15","author":"C Capatina","year":"2020","unstructured":"Capatina C, Hinojosa-Amaya JM, Poiana C, Fleseriu M (2020) Management of patients with persistent or recurrent Cushing\u2019s disease after initial pituitary surgery. Expert Rev Endocrinol Metab 15:321\u2013339. https:\/\/doi.org\/10.1080\/17446651.2020.1802243","journal-title":"Expert Rev Endocrinol Metab"},{"key":"1218_CR31","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s11102-020-01066-8","volume":"23","author":"A Stroud","year":"2020","unstructured":"Stroud A, Dhaliwal P, Alvarado R et al (2020) Outcomes of pituitary surgery for Cushing\u2019s disease: a systematic review and meta-analysis. Pituitary 23:595\u2013609. https:\/\/doi.org\/10.1007\/s11102-020-01066-8","journal-title":"Pituitary"},{"key":"1218_CR32","doi-asserted-by":"publisher","first-page":"bvab109","DOI":"10.1210\/jendso\/bvab109","volume":"5","author":"R Acree","year":"2021","unstructured":"Acree R, Miller CM, Abel BS et al (2021) Patient and Provider Perspectives on Postsurgical Recovery of Cushing Syndrome. J Endocr Soc 5:bvab109. https:\/\/doi.org\/10.1210\/jendso\/bvab109","journal-title":"J Endocr Soc"},{"key":"1218_CR33","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s11154-010-9140-6","volume":"11","author":"D AbdelMannan","year":"2010","unstructured":"AbdelMannan D, Selman WR, Arafah BM (2010) Peri-operative management of Cushing\u2019s disease. Rev Endocr Metab Disord 11:127\u2013134. https:\/\/doi.org\/10.1007\/s11154-010-9140-6","journal-title":"Rev Endocr Metab Disord"},{"key":"1218_CR34","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/cen.12300","volume":"80","author":"F Costenaro","year":"2014","unstructured":"Costenaro F, Rodrigues TC, Rollin GAF et al (2014) Evaluation of Cushing\u2019s disease remission after transsphenoidal surgery based on early serum cortisol dynamics. Clin Endocrinol (Oxf) 80:411\u2013418. https:\/\/doi.org\/10.1111\/cen.12300","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1218_CR35","doi-asserted-by":"publisher","first-page":"bvac010","DOI":"10.1210\/jendso\/bvac010","volume":"6","author":"EV Varlamov","year":"2022","unstructured":"Varlamov EV, Vila G, Fleseriu M (2022) Perioperative Management of a Patient With Cushing Disease. J Endocr Soc 6:bvac010. https:\/\/doi.org\/10.1210\/jendso\/bvac010","journal-title":"J Endocr Soc"},{"key":"1218_CR36","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1210\/jc.2017-01797","volume":"103","author":"N El Asmar","year":"2018","unstructured":"El Asmar N, Rajpal A, Selman WR, Arafah BM (2018) The Value of Perioperative Levels of ACTH, DHEA, and DHEA-S and Tumor Size in Predicting Recurrence of Cushing Disease. J Clin Endocrinol Metab 103:477\u2013485. https:\/\/doi.org\/10.1210\/jc.2017-01797","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR37","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1210\/clinem\/dgab698","volume":"107","author":"OM DeLozier","year":"2022","unstructured":"DeLozier OM, Dream SY, Findling JW et al (2022) Selective Glucocorticoid Replacement Following Unilateral Adrenalectomy for Hypercortisolism and Primary Aldosteronism. J Clin Endocrinol Metab 107:e538\u2013e547. https:\/\/doi.org\/10.1210\/clinem\/dgab698","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR38","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1210\/jc.2011-1661","volume":"96","author":"DJF Stuijver","year":"2011","unstructured":"Stuijver DJF, van Zaane B, Feelders RA et al (2011) Incidence of venous thromboembolism in patients with Cushing\u2019s syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96:3525\u20133532. https:\/\/doi.org\/10.1210\/jc.2011-1661","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR39","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/cen.12094","volume":"78","author":"R van der Pas","year":"2013","unstructured":"van der Pas R, Leebeek FWG, Hofland LJ et al (2013) Hypercoagulability in Cushing\u2019s syndrome: prevalence, pathogenesis and treatment. Clin Endocrinol (Oxf) 78:481\u2013488. https:\/\/doi.org\/10.1111\/cen.12094","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1218_CR40","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1210\/jc.2011-2753","volume":"97","author":"R van der Pas","year":"2012","unstructured":"van der Pas R, de Bruin C, Leebeek FWG et al (2012) The hypercoagulable state in Cushing\u2019s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab 97:1303\u20131310. https:\/\/doi.org\/10.1210\/jc.2011-2753","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR41","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3171\/2008.9.JNS08191","volume":"111","author":"RA Kristof","year":"2009","unstructured":"Kristof RA, Rother M, Neuloh G, Klingm\u00fcller D (2009) Incidence, clinical manifestations, and course of water and electrolyte metabolism disturbances following transsphenoidal pituitary adenoma surgery: a prospective observational study: Clinical article. J Neurosurg 111:555\u2013562. https:\/\/doi.org\/10.3171\/2008.9.JNS08191","journal-title":"J Neurosurg"},{"key":"1218_CR42","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.nec.2019.05.011","volume":"30","author":"KCJ Yuen","year":"2019","unstructured":"Yuen KCJ, Ajmal A, Correa R, Little AS (2019) Sodium Perturbations After Pituitary Surgery. Neurosurg Clin 30:515\u2013524. https:\/\/doi.org\/10.1016\/j.nec.2019.05.011","journal-title":"Neurosurg Clin"},{"key":"1218_CR43","doi-asserted-by":"publisher","DOI":"10.1055\/s-0041-1729980","author":"MK Ghiam","year":"2021","unstructured":"Ghiam MK, Chyou DE, Dable CL et al (2021) 30-Day Readmissions and Coordination of Care Following Endoscopic Transsphenoidal Pituitary Surgery: Experience with 409 Patients. J Neurol Surg Part B Skull Base. https:\/\/doi.org\/10.1055\/s-0041-1729980","journal-title":"J Neurol Surg Part B Skull Base"},{"key":"1218_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1227\/NEU.0000000000001003","volume":"78","author":"MA Bohl","year":"2016","unstructured":"Bohl MA, Ahmad S, Jahnke H et al (2016) Delayed Hyponatremia Is the Most Common Cause of 30-Day Unplanned Readmission After Transsphenoidal Surgery for Pituitary Tumors. Neurosurgery 78:84\u201390. https:\/\/doi.org\/10.1227\/NEU.0000000000001003","journal-title":"Neurosurgery"},{"key":"1218_CR45","first-page":"1085","volume":"108","author":"GM Doherty","year":"1990","unstructured":"Doherty GM, Nieman LK, Cutler GB et al (1990) Time to recovery of the hypothalamic-pituitary-adrenal axis after curative resection of adrenal tumors in patients with Cushing\u2019s syndrome. Surgery 108:1085\u20131090","journal-title":"Surgery"},{"key":"1218_CR46","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/j.surg.2008.08.024","volume":"144","author":"RS Sippel","year":"2008","unstructured":"Sippel RS, Elaraj DM, Kebebew E et al (2008) Waiting for change: Symptom resolution after adrenalectomy for Cushing\u2019s syndrome. Surgery 144:1054\u20131061. https:\/\/doi.org\/10.1016\/j.surg.2008.08.024","journal-title":"Surgery"},{"key":"1218_CR47","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/j.1552-4604.1991.tb01906.x","volume":"31","author":"H Derendorf","year":"1991","unstructured":"Derendorf H, M\u00f6llmann H, Barth J et al (1991) Pharmacokinetics and Oral Bioavailability of Hydrocortisone. J Clin Pharmacol 31:473\u2013476. https:\/\/doi.org\/10.1002\/j.1552-4604.1991.tb01906.x","journal-title":"J Clin Pharmacol"},{"key":"1218_CR48","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1507\/endocrj1954.33.203","volume":"33","author":"K Suzuki","year":"1986","unstructured":"Suzuki K, Nonaka K, Ichihara K et al (1986) Hypercalcemia in Glucocorticoid Withdrawal. Endocrinol Jpn 33:203\u2013209. https:\/\/doi.org\/10.1507\/endocrj1954.33.203","journal-title":"Endocrinol Jpn"},{"key":"1218_CR49","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-021-00619-5","author":"Y Oyama","year":"2021","unstructured":"Oyama Y, Iwafuchi Y, Narita I (2021) A case of hypercalcemia because of adrenal insufficiency induced by glucocorticoid withdrawal in a patient undergoing hemodialysis. CEN Case Rep. https:\/\/doi.org\/10.1007\/s13730-021-00619-5","journal-title":"CEN Case Rep"},{"key":"1218_CR50","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1210\/jc.2014-3632","volume":"100","author":"CM Berr","year":"2015","unstructured":"Berr CM, Di Dalmazi G, Osswald A et al (2015) Time to Recovery of Adrenal Function After Curative Surgery for Cushing\u2019s Syndrome Depends on Etiology. J Clin Endocrinol Metab 100:1300\u20131308. https:\/\/doi.org\/10.1210\/jc.2014-3632","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.21608\/esj.2020.34844.1140","volume":"35","author":"HEM Gad","year":"2020","unstructured":"Gad HEM, Ismail AM (2020) The role of vertebroplasty in steroid-induced vertebral osteoporotic fractures. Egypt Spine J 35:41\u201352. https:\/\/doi.org\/10.21608\/esj.2020.34844.1140","journal-title":"Egypt Spine J"},{"key":"1218_CR52","doi-asserted-by":"publisher","first-page":"e4490","DOI":"10.1210\/clinem\/dgaa625","volume":"105","author":"F Vogel","year":"2020","unstructured":"Vogel F, Braun LT, Rubinstein G et al (2020) Persisting Muscle Dysfunction in Cushing\u2019s Syndrome Despite Biochemical Remission. J Clin Endocrinol Metab 105:e4490\u2013e4498. https:\/\/doi.org\/10.1210\/clinem\/dgaa625","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR53","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1530\/EJE-20-1285","volume":"184","author":"F Vogel","year":"2021","unstructured":"Vogel F, Braun L, Rubinstein G et al (2021) Patients with low IGF-I after curative surgery for Cushing\u2019s syndrome have an adverse long-term outcome of hypercortisolism-induced myopathy. Eur J Endocrinol 184:813\u2013821. https:\/\/doi.org\/10.1530\/EJE-20-1285","journal-title":"Eur J Endocrinol"},{"key":"1218_CR54","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-14-1101","volume":"173","author":"CD Andela","year":"2015","unstructured":"Andela CD, van Haalen FM, Ragnarsson O et al (2015) MECHANISMS IN ENDOCRINOLOGY: Cushing\u2019s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur J Endocrinol 173:R1\u2013R14. https:\/\/doi.org\/10.1530\/EJE-14-1101","journal-title":"Eur J Endocrinol"},{"key":"1218_CR55","doi-asserted-by":"publisher","first-page":"101505","DOI":"10.1016\/j.beem.2021.101505","volume":"35","author":"MM Bride","year":"2021","unstructured":"Bride MM, Crespo I, Webb SM, Valassi E (2021) Quality of life in Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 35:101505. https:\/\/doi.org\/10.1016\/j.beem.2021.101505","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"1218_CR56","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/0006-3223(92)90079-F","volume":"32","author":"MN Starkman","year":"1992","unstructured":"Starkman MN, Gebarski SS, Berent S, Schteingart DE (1992) Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing\u2019s syndrome. Biol Psychiatry 32:756\u2013765. https:\/\/doi.org\/10.1016\/0006-3223(92)90079-F","journal-title":"Biol Psychiatry"},{"key":"1218_CR57","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1192\/S0007125000296645","volume":"160","author":"BS McEwen","year":"1992","unstructured":"McEwen BS, Gould EA, Sakai RR (1992) The Vulnerability of the Hippocampus to Protective and Destructive Effects of Glucocorticoids in Relation to Stress. Br J Psychiatry 160:18\u201323. https:\/\/doi.org\/10.1192\/S0007125000296645","journal-title":"Br J Psychiatry"},{"key":"1218_CR58","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1210\/jc.2004-1375","volume":"90","author":"MO van Aken","year":"2005","unstructured":"van Aken MO, Pereira AM, Biermasz NR et al (2005) Quality of Life in Patients after Long-Term Biochemical Cure of Cushing\u2019s Disease. J Clin Endocrinol Metab 90:3279\u20133286. https:\/\/doi.org\/10.1210\/jc.2004-1375","journal-title":"J Clin Endocrinol Metab"},{"key":"1218_CR59","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.neubiorev.2012.10.005","volume":"37","author":"CF Zorumski","year":"2013","unstructured":"Zorumski CF, Paul SM, Izumi Y et al (2013) Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci Biobehav Rev 37:109\u2013122. https:\/\/doi.org\/10.1016\/j.neubiorev.2012.10.005","journal-title":"Neurosci Biobehav Rev"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01218-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01218-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T21:08:25Z","timestamp":1654549705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01218-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,26]]},"references-count":59,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["1218"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01218-y","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,26]]},"assertion":[{"value":"15 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statements and Declarations"}},{"value":"Dr. Auchus has received research support from Novartis Pharmaceuticals, Corcept Therapeutics, Spruce Biosciences, and Neurocrine Biosciences and has served as a consultant for Corcept Therapeutics, Janssen Pharmaceuticals, Novartis Pharmaceuticals, Quest Diagnostics, Adrenas Therapeutics, Crinetics Pharmaceuticals, PhaseBio Pharmaceuticals, OMass Therapeutics, Recordati Rare Diseases, Strongbridge Biopharma, and H Lundbeck A\/S. Dr. Findling has received research support from Novartis Pharmaceuticals and has served as a consultant for Corcept Therapeutics and Recordati Rare Diseases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Financial Interests"}},{"value":"No human subjects or animals were used to collect data for this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human Subjects and Animals"}}]}}